An FDA committee will soon make recommendations about this fall’s Covid-19 vaccines while Novavax still awaits full FDA approval for its shot.

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a few days of dosing. None of the companies involved have commented on the change in the warning text.

mRNA vaccines made by Pfizer and Moderna, have earned full FDA approval for certain age groups. Because the coronavirus continually mutates, manufacturers follow instructions from FDA to make one ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.